Global Fat Reduction Market - Industry Trends and Forecast to 2030

TABLE OF CONTENTS

1 INTRODUCTION 227

• 1.1 OBJECTIVES OF THE STUDY 227
• 1.2 MARKET DEFINITION 227
• 1.3 OVERVIEW OF THE GLOBAL FAT REDUCTION MARKET 227
• 1.4 CURRENCY AND PRICING 229
• 1.5 LIMITATIONS 229
• 1.6 MARKETS COVERED 230

2 MARKET SEGMENTATION 235

• 2.1 MARKETS COVERED 235
• 2.2 GEOGRAPHICAL SCOPE 236
• 2.3 YEARS CONSIDERED FOR THE STUDY 237
• 2.4 DBMR TRIPOD DATA VALIDATION MODEL 238
• 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 241
• 2.6 MULTIVARIATE MODELLING 242
• 2.7 TYPE LIFELINE CURVE 242
• 2.8 DBMR MARKET POSITION GRID 243
• 2.9 VENDOR SHARE ANALYSIS 244
• 2.10 MARKET APPLICATION COVERAGE GRID 245
• 2.11 SECONDARY SOURCES 246
• 2.12 ASSUMPTIONS 246

3 EXECUTIVE SUMMARY 247

4 PREMIUM INSIGHT 251

• 4.1 PESTEL ANALYSIS 253
• 4.2 PORTER'S FIVE FORCES 254
• 4.3 MARKET ANALYSIS 255
• 4.4 NORTH AMERICA (PRICING AND PROCEDURE ANALYSIS) 256
  • 4.4.1 U.S. 256
  • 4.4.2 CANADA 257
  • 4.4.3 MEXICO 258
  • 4.4.4 COSTA RICA 259
  • 4.4.5 DOMINICIAN REPUBLIC 260
  • 4.4.6 PANAMA 261
  • 4.4.7 EL SALVADOR 262
  • 4.4.8 GAUTEMALA 263
  • 4.4.9 HONDURAS 264
  • 4.4.10 NICARAGUA 265
• 4.5 EUROPE (PRICING AND PROCEDURE ANALYSIS) 266
  • 4.5.1 GERMANY 266
  • 4.5.2 TURKEY 267
  • 4.5.3 ITALY 268
  • 4.5.4 POLAND 269
  • 4.5.5 SPAIN 270
  • 4.5.6 RUSSIA 271
  • 4.5.7 FRANCE 272
  • 4.5.8 NETHERLANDS 273
  • 4.5.9 SWITZERLAND 274
  • 4.5.10 BELIGUM 275
  • 4.5.11 AUSTRIA 276
  • 4.5.12 NORWAY 277
  • 4.5.13 IRELAND 278
  • 4.5.14 HUNGARY 279
  • 4.5.15 LITHUAMIA 280
  • 4.5.16 AZERBAIJAN 281
  • 4.5.17 U.K. 282
  • 4.5.18 GEORGIA 283
  • 4.5.19 UKRAINE 284
• 4.6 ASIA PACIFIC (PRICING AND PROCEDURE ANALYSIS) 285
  • 4.6.1 JAPAN 285
  • 4.6.2 INDIA 286
  • 4.6.3 CHINA 287
  • 4.6.4 SOUTH KOREA 288
  • 4.6.5 THAILAND 289
  • 4.6.6 MALAYSIA 290
  • 4.6.7 SINGAPORE 291
  • 4.6.8 AUSTRALIA 292
  • 4.6.9 PHILIPPINES 293
  • 4.6.10 TAIWAN 294
  • 4.6.11 INDONESIA 295
  • 4.6.12 NEW ZEALAND 296
  • 4.6.13 VIETNAM 297
  • 4.6.14 PAKISTAN 298
  • 4.6.15 UZBEKISTAN 299
  • 4.6.16 MYANMAR 300
  • 4.6.17 NEPAL 301
  • 4.6.18 COMBODIA 302
• 4.7 MIDDLE EAST & AFRICA (PRICING AND PROCEDURE ANALYSIS) 303
  • 4.7.1 SAUDI ARABIA 303
  • 4.7.2 EGYPT 304
  • 4.7.3 UAE 305
  • 4.7.4 SOUTH AFRICA 306
  • 4.7.5 ISRAEL 307
  • 4.7.6 KUWAIT 308
  • 4.7.7 QATAR 309
  • 4.7.8 OMAN 310
  • 4.7.9 BAHRAIN 311
  • 4.7.10 LEBANON 312
  • 4.7.11 ALGERIA 313
  • 4.7.12 JORDAN 314
  • 4.7.13 MOROCCO 315
  • 4.7.14 IRAN 316
  • 4.7.15 LIBIYA 317
  • 4.7.16 IRAQ 318
  • 4.7.17 TUNISIA 319
• 4.8 SOUTH AMERICA (PRICING AND PROCEDURE ANALYSIS) 320
  • 4.8.1 BRAZIL 320
  • 4.8.2 ARGENTINA 321
  • 4.8.3 COLOMBIA 322
  • 4.8.4 CHILE 323
  • 4.8.5 PERU 324
  • 4.8.6 EQUADOR 325
  • 4.8.7 BOLIVIA 326
  • 4.8.8 PARAGUAY 327
• 4.9 BRAND ANALYSIS 328
  • 4.9.1 KYBELLA 328
  • 4.9.2 AQUALYX 329
• 4.10 PRICING ANALYSIS (USD) 330
  • 4.10.1 NORTH AMERICA 330
    • 4.10.1.1 U.S. 330
    • 4.10.1.2 CANADA 330
    • 4.10.1.3 MEXICO 330
    • 4.10.1.4 COSTA RICA 331
    • 4.10.1.5 DOMINICIAN REPUBLIC 331
    • 4.10.1.6 PANAMA 331
    • 4.10.1.7 EL SALVADOR 332
    • 4.10.1.8 GAUTEMALA 332
    • 4.10.1.9 HONDURAS 332
    • 4.10.1.10 NICARAGUA 333
  • 4.10.2 EUROPE 334
    • 4.10.2.1 GERMANY 334
    • 4.10.2.2 TURKEY 334
    • 4.10.2.3 ITALY 334
    • 4.10.2.4 POLAND 335
    • 4.10.2.5 SPAIN 335
    • 4.10.2.6 RUSSIA 335
    • 4.10.2.7 FRANCE 336
    • 4.10.2.8 NETHERLANDS 336
    • 4.10.2.9 SWITZERLAND 336
    • 4.10.2.10 BELIGUM 337
    • 4.10.2.11 AUSTRIA 337
    • 4.10.2.12 NORWAY 337
    • 4.10.2.13 IRELAND 338
    • 4.10.2.14 HUNGARY 338
    • 4.10.2.15 LITHUAMIA 338
    • 4.10.2.16 AZERBAIJAN 339
    • 4.10.2.17 U.K. 339
    • 4.10.2.18 GEORGIA 339
    • 4.10.2.19 UKRAINE 340
  • 4.10.3 ASIA-PACIFIC 341
    • 4.10.3.1 JAPAN 341
    • 4.10.3.2 INDIA 341
    • 4.10.3.3 CHINA 341
    • 4.10.3.4 SOUTH KOREA 342
    • 4.10.3.5 THAILAND 342
    • 4.10.3.6 MALAYSIA 342
    • 4.10.3.7 SINGAPORE 343
    • 4.10.3.8 AUSTRALIA 343
    • 4.10.3.9 PHILIPPINES 343
    • 4.10.3.10 TAIWAN 344
    • 4.10.3.11 INDONESIA 344
    • 4.10.3.12 NEW ZEALAND 344
    • 4.10.3.13 VIETNAM 345
    • 4.10.3.14 PAKISTAN 345
    • 4.10.3.15 UZBEKISTAN 345
    • 4.10.3.16 MYANMAR 346
    • 4.10.3.17 NEPAL 346
    • 4.10.3.18 COMBODIA 346
  • 4.10.4 SOUTH AMERICA 347
    • 4.10.4.1 BRAZIL 347
    • 4.10.4.2 ARGENTINA 347
    • 4.10.4.3 COLOMBIA 347
    • 4.10.4.4 CHILE 348
    • 4.10.4.5 PERU 348
    • 4.10.4.6 EQUADOR 348
    • 4.10.4.7 BOLIVIA 349
    • 4.10.4.8 PARAGUAY 349
  • 4.10.5 MIDDLE EAST & AFRICA 350
    • 4.10.5.1 SAUDI ARABIA 350
    • 4.10.5.2 EGYPT 350
    • 4.10.5.3 UAE 350
    • 4.10.5.4 SOUTH AFRICA 351
    • 4.10.5.5 ISRAEL 351
    • 4.10.5.6 KUWAIT 351
    • 4.10.5.7 QATAR 352
    • 4.10.5.8 OMAN 352
    • 4.10.5.9 BAHRAIN 352
    • 4.10.5.10 LEBANON 352
    • 4.10.5.11 ALGERIA 353
    • 4.10.5.12 JORDAN 353
    • 4.10.5.13 MOROCCO 353
    • 4.10.5.14 IRAN 353
    • 4.10.5.15 LIBIYA 354
    • 4.10.5.16 IRAQ 354
    • 4.10.5.17 TUNISIA 354
• 4.11 PATENT ANALYSIS OF THE GLOBAL FAT REDUCTION MARKET 355
  • 4.11.1 U.S. 355
    • 4.11.1.1 METHODS FOR THE PURIFICATION OF DEOXYCHOLIC ACID 355
    • 4.11.1.2 COMPOSITIONS COMPRISING DEOXYCHOLIC ACID AND SALTS THEREOF SUITABLE FOR USE IN TREATING EAT DEPOSITS 356
    • 4.11.1.3 FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF 357
    • 4.11.1.4 SYNTHETIC BILE ACID COMPOSITIONS AND METHODS 357
  • 4.11.2 CANADA 358
    • 4.11.2.1 SYNTHETIC BILE ACID COMPOSITIONS AND METHODS 358
    • 4.11.2.2 BELKYRA 358
    • 4.11.2.3 BELKYRA 359
    • 4.11.2.4 BELKYRA 359
  • 4.11.3 MEXICO 360
    • 4.11.3.1 FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF. 360
    • 4.11.3.2 TREATMENTS OF ACCUMULATED FAT WITH DEOXYCHOLIC ACID AND SALTS THEREOF. 360
  • 4.11.4 EUROPE 361
    • 4.11.4.1 FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF 361
    • 4.11.4.2 SYNTHESIS OF DEOXYCHOLIC ACID (DCA) 362
    • 4.11.4.3 METHOD AND COMPOSITION FOR REDUCING SUBCUTANEOUS FAT 363
    • 4.11.4.4 METHOD AND COMPOSITION FOR REDUCING SUBCUTANEOUS FAT DEPOSITS 364
  • 4.11.5 HUNGARY 365
    • 4.11.5.1 FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF 365
  • 4.11.6 JAPAN 365
    • 4.11.6.1 FORMULATION OF DEOXYCHOLIC ACID AND ITS SALTS 365
    • 4.11.6.2 METHOD FOR TREATING ACCUMULATED FAT WITH DEOXYCHOLIC ACID AND ITS SALTS 366
    • 4.11.6.3 FORMULATION OF DEOXYCHOLIC ACID AND ITS SALTS 366
    • 4.11.6.4 FORMULATION OF DEOXYCHOLIC ACID AND ITS SALTS 367
  • 4.11.7 AUSTRALIA 367
    • 4.11.7.1 TREATMENTS OF ACCUMULATED FAT WITH DEOXYCHOLIC ACID AND SALTS THEREOF 367
    • 4.11.7.2 FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF 368
  • 4.11.8 CHINA 369
    • 4.11.8.1 THE PREPARATION OF DEOXYCHOLIC ACID AND ITS SALT 369
    • 4.11.8.2 FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF 369
    • 4.11.8.3 TREATMENT USING DEOXYCHOLIC ACID AND ITS SALT TO THE FAT OF ACCUMULATION 370
  • 4.11.9 SOUTH AFRICA 371
    • 4.11.9.1 FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF 371
  • 4.11.10 INDIA 371
  • 4.11.11 SOUTH KOREA 371
• 4.12 PRICING ANALYSIS (USD) 373
  • 4.12.1 KYBELLA 373
  • 4.12.2 COOLSCULPTING 375
  • 4.12.3 COOLSCULPTING ELITE 377
  • 4.12.4 COOLTONE 379

5 INDUSTRY INSIGHTS: 382

• 5.1 DEMOGRAPHIC TRENDS: 383
• 5.2 CONCLUSION: 384

6 GLOBAL FAT REDUCTION MARKET, REGULATIONS 385

• 6.1 U.S. 385
  • 6.1.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE: 385
  • 6.1.2 POST-MARKETING SURVEILLANCE: 387
  • 6.1.3 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES: 387
• 6.2 CANADA 388
  • 6.2.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 388
  • 6.2.2 LICENSING AND REGISTRATION 389
  • 6.2.3 POST EXPIRY OF PATENT REGIME 389
  • 6.2.4 POST-MARKETING SURVEILLANCE 389
• 6.3 MEXICO 390
  • 6.3.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 390
  • 6.3.2 REGULATORY APPROVAL AGENCIES 390
  • 6.3.3 LICENSING AND REGISTRATION 391
  • 6.3.4 POST-MARKETING SURVEILLANCE 391
• 6.4 DOMINICAN REPUBLIC 391
  • 6.4.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 391
  • 6.4.2 RENEWAL OF REGISTRATION IS REQUIRED IF THERE IS A CHANGE IN PRODUCT FORMULATION OR A CHANGE IN THE SITE OF MANUFACTURE. 392
  • 6.4.3 TIMELINE 393
• 6.5 GUATEMALA 393
  • 6.5.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 393
  • 6.5.2 REGULATORY APPROVAL AGENCIES 393
  • 6.5.3 LICENSING AND REGISTRATION 394
  • 6.5.4 POST-MARKETING SURVEILLANCE 394
  • 6.5.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 394

• 6.6 HONDURAS 394
  • 6.6.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 394
  • 6.6.2 REGULATORY APPROVAL AGENCIES 394
• 6.7 NICARAGUA 395
  • 6.7.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 395
  • 6.7.2 LICENSING AND REGISTRATION 395
  • 6.7.3 POST-MARKETING SURVEILLANCE 395
• 6.8 GERMANY 395
  • 6.8.1 REGULATORY APPROVAL AGENCIES AND PROCESS 395
• 6.9 FRANCE 396
  • 6.9.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 396
  • 6.9.2 REGULATORY APPROVAL AGENCIES 396
  • 6.9.3 POST-MARKETING SURVEILLANCE 396
• 6.10 U.K. 396
  • 6.10.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 396
  • 6.10.2 GENERIC MARKET 397
  • 6.10.3 REGULATORY APPROVAL AGENCIES 397
  • 6.10.4 LICENSING AND REGISTRATION 398
  • 6.10.5 POST-MARKETING SURVEILLANCE 399
• 6.11 ITALY 399
  • 6.11.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 399
  • 6.11.2 REGULATORY APPROVAL AGENCIES 399
  • 6.11.3 LICENSING AND REGISTRATION 400
  • 6.11.4 POST-MARKETING SURVEILLANCE 400
  • 6.11.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 400
• 6.12 SPAIN 400
  • 6.12.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 400
  • 6.12.2 REGULATORY APPROVAL AGENCIES 400
  • 6.12.3 LICENSING AND REGISTRATION 400
• 6.13 RUSSIA 401
  • 6.13.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 401
  • 6.13.2 TIMELINE 401
  • 6.13.3 REGULATORY APPROVAL AGENCIES 401
  • 6.13.4 LICENSING AND REGISTRATION 401
  • 6.13.5 GOOD MANUFACTURING PRACTICES 402
  • 6.13.6 TIMELINES FOR RUSSIAN GMP CERTIFICATE 402
• 6.14 TURKEY 403
  • 6.14.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 403
  • 6.14.2 REGULATORY APPROVAL AGENCIES 403
  • 6.14.3 LICENSING AND REGISTRATION 403
  • 6.14.4 POST-MARKETING SURVEILLANCE 404
  • 6.14.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 404
• 6.15 AZERBAIJAN 404
  • 6.15.1 THE FOLLOWING TERMS ARE USED IN THE PRESENT REGULATIONS: 404
  • 6.15.2 PROCEDURE OF SUBMITTING FOR STATE REGISTRATION 405
  • 6.15.3 LICENSING 406
• 6.16 UKRAINE 406
  • 6.16.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 406
  • 6.16.2 REGULATORY APPROVAL AGENCIES 406
  • 6.16.3 LICENSING AND REGISTRATION 407
  • 6.16.4 POST-MARKETING SURVEILLANCE 408
• 6.17 BELGIUM 409
  • 6.17.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 409
  • 6.17.2 REGULATORY APPROVAL AGENCIES 409
  • 6.17.3 LICENSING AND REGISTRATION 409
• 6.18 HUNGARY 409
  • 6.18.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 409
  • 6.18.2 REGULATORY APPROVAL AGENCIES 409
  • 6.18.3 LICENSING AND REGISTRATION 410
  • 6.18.4 POST-MARKETING SURVEILLANCE 410
• 6.19 LITHUANIA 410
  • 6.19.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 410
  • 6.19.2 REGULATORY APPROVAL AGENCIES 411
• 6.20 AUSTRIA 411
  • 6.20.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 411
  • 6.20.2 REGULATORY APPROVAL AGENCIES 411
  • 6.20.3 LICENSING AND REGISTRATION 411
  • 6.20.4 POST-MARKETING SURVEILLANCE 411
• 6.21 IRELAND 412
  • 6.21.1 REGULATORY APPROVAL AGENCIES 412
• 6.22 NORWAY 413
  • 6.22.1 REGULATORY APPROVAL AGENCIES AND APPROVAL PROCESS 413
• 6.23 NETHERLANDS 414
  • 6.23.1 REGULATORY APPROVAL AGENCIES AND APPROVAL PROCESS 414
• 6.24 SWITZERLAND 414
  • 6.24.1 REGULATORY APPROVAL AGENCIES AND APPROVAL PROCESS 414
• 6.25 JAPAN 415
  • 6.25.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 415
  • 6.25.2 REGULATORY APPROVAL AGENCIES 415
  • 6.25.3 REVIEW, CATEGORIZE, AND PERFORM INGREDIENT ANALYSIS FOR THE AESTHETIC PRODUCT. 415
  • 6.25.4 OBTAINING REQUIRED LICENSES. 416
  • 6.25.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 416
  • 6.25.6 COSMETIC & QUASI-DRUG MARKETING NOTIFICATION SUBMISSION. 416
  • 6.25.7 IMPORT THE COSMETICS AND QUASI DRUGS INTO JAPAN. 416
  • 6.25.8 PRIMARY DISTRIBUTION APPROVAL 416
  • 6.25.9 COSMETIC MANUFACTURING LICENSE (PACKAGING, LABELING, AND STORAGE). 416
• 6.26 CHINA 417
  • 6.26.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 417
  • 6.26.2 LICENSING AND REGISTRATION 417
  • 6.26.3 REGULATORY APPROVAL AGENCIES 418
  • 6.26.4 POST-MARKETING SURVEILLANCE 418
• 6.27 SOUTH KOREA 418
  • 6.27.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 418
  • 6.27.2 REGULATORY APPROVAL AGENCIES 419
  • 6.27.3 LICENSING AND REGISTRATION 419
  • 6.27.4 POST-MARKETING SURVEILLANCE 419
  • 6.27.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 419
• 6.28 INDIA 419
  • 6.28.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 419
  • 6.28.2 LICENSING AND REGISTRATION 420
  • 6.28.3 REGULATORY APPROVAL AGENCIES 421
  • 6.28.4 POST-MARKETING SURVEILLANCE 421
• 6.29 AUSTRALIA 421
  • 6.29.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 421
  • 6.29.2 REGULATORY APPROVAL AGENCIES 422
  • 6.29.3 LICENSING AND REGISTRATION 422
  • 6.29.4 POST-MARKETING SURVEILLANCE 422
  • 6.29.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 422
• 6.30 SINGAPORE 422
  • 6.30.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 422
  • 6.30.2 REGULATORY APPROVAL AGENCIES 422
  • 6.30.3 LICENSING AND REGISTRATION 423
  • 6.30.4 POST-MARKETING SURVEILLANCE 423
  • 6.30.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 423
• 6.31 THAILAND 423
  • 6.31.1 THAILAND DRUG REGISTRATION 423
  • 6.31.2 GENERIC DRUG 423
• 6.32 MALAYSIA 425
  • 6.32.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 425
  • 6.32.2 REGULATORY APPROVAL AGENCIES 425
  • 6.32.3 LICENSING AND REGISTRATION 425
  • 6.32.4 POST-MARKETING SURVEILLANCE 425
• 6.33 INDONESIA 426
  • 6.33.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 426
  • 6.33.2 REGULATORY APPROVAL AGENCIES 426
  • 6.33.3 LICENSING AND REGISTRATION 426
• 6.34 PHILIPPINES 426
  • 6.34.1 GET A LICENSE TO OPERATE FROM THE FDA IN THE PHILIPPINES: 427
• 6.35 NEW ZEALAND 428
  • 6.35.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 428
  • 6.35.2 TIMELINE 428
  • 6.35.3 REGULATORY APPROVAL AGENCIES 428
  • 6.35.4 LICENSING AND REGISTRATION 429
  • 6.35.5 GOOD CLINICAL PRACTICE REQUIREMENTS 429
• 6.36 TAIWAN 429
  • 6.36.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 429
  • 6.36.2 TIMELINE: 430
  • 6.36.3 REGULATORY APPROVAL AGENCIES 430
  • 6.36.4 POST MARKETING SURVEILLANCE 430
• 6.37 CAMBODIA 430
  • 6.37.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 430
  • 6.37.2 REGULATORY APPROVAL AGENCIES 432
  • 6.37.3 LICENSING AND REGISTRATION 432
  • 6.37.4 POST-MARKETING SURVEILLANCE 432
• 6.38 NEPAL 433
  • 6.38.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 433
  • 6.38.2 REGULATORY APPROVAL AGENCIES 433
• 6.39 PAKISTAN 433
  • 6.39.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 433
  • 6.39.2 REGULATORY APPROVAL AGENCIES 433
  • 6.39.3 LICENSING AND REGISTRATION 433
• 6.40 UZBEKISTAN 434
  • 6.40.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 434
  • 6.40.2 REGULATORY APPROVAL AGENCIES 434
  • 6.40.3 LICENSING AND REGISTRATION 434
• 6.41 VIETNAM 434
  • 6.41.1 REGULATORY APPROVAL TIMELINE 434
  • 6.41.2 REGULATORY APPROVAL AGENCIES 434
  • 6.41.3 LICENSING AND REGISTRATION 434
• 6.42 BRAZIL 435
  • 6.42.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE: 435
  • 6.42.2 REGULATORY APPROVAL AGENCIES: 436
  • 6.42.3 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 437
• 6.43 ARGENTINA 437
  • 6.43.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 437
  • 6.43.2 REGULATORY APPROVAL AGENCIES 439
  • 6.43.3 LICENSING AND REGISTRATION 439
• 6.44 CHILE 440
  • 6.44.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 440
  • 6.44.2 REGULATORY APPROVAL AGENCIES 441
  • 6.44.3 LICENSING AND REGISTRATION 441
• 6.45 PERU 441
  • 6.45.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 441
• 6.46 COLOMBIA 442
  • 6.46.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 442
  • 6.46.2 LICENSING AND REGISTRATION 442
  • 6.46.3 REGULATORY APPROVAL AGENCIES 442
• 6.47 ECUADOR 443
  • 6.47.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 443
  • 6.47.2 REGULATORY APPROVAL AGENCIES 443
  • 6.47.3 LICENSING AND REGISTRATION 443
  • 6.47.4 POST-MARKETING SURVEILLANCE 444
• 6.48 BOLIVIA 444
  • 6.48.1 REGULATORY AUTHORITY 444
  • 6.48.2 THE REGULATORY FRAMEWORK FOR THE AUTHORIZATION OF DRUGS AND BIOLOGICALS 444
  • 6.48.3 PATHWAYS TO OBTAIN AUTHORIZATION TO DEVELOP, TEST, AND MARKET A PRODUCT 444
  • 6.48.4 MARKETING AUTHORIZATIONS/REGISTRATIONS VALID 444
  • 6.48.5 AUTHORIZATION PROCESS BETWEEN BRAND-NAME PRODUCTS AND GENERIC PRODUCTS 444
• 6.49 SOUTH AFRICA 445
  • 6.49.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 445
  • 6.49.2 REGULATORY APPROVAL AGENCIES 445
  • 6.49.3 LICENSING AND REGISTRATION 445
  • 6.49.4 POST-MARKETING SURVEILLANCE 446
• 6.50 SAUDI ARABIA 446
  • 6.50.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 446
  • 6.50.2 REGULATORY APPROVAL AGENCIES 446
  • 6.50.3 LICENSING AND REGISTRATION 447
  • 6.50.4 POST-MARKETING SURVEILLANCE 447
  • 6.50.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 447
• 6.51 UAE 448
  • 6.51.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 448
  • 6.51.2 LICENSING AND REGISTRATION 449
  • 6.51.3 REGULATORY APPROVAL AGENCIES 450
  • 6.51.4 GOOD MANUFACTURING PRACTICES (GMPS) 450
• 6.52 EGYPT 450
  • 6.52.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 450
  • 6.52.2 REGULATORY APPROVAL AGENCIES 450
  • 6.52.3 LICENSING AND REGISTRATION 451
  • 6.52.4 POST-MARKETING SURVEILLANCE 451
  • 6.52.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 451
• 6.53 KUWAIT 451
  • 6.53.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 451
  • 6.53.2 REGULATORY APPROVAL AGENCIES 452
  • 6.53.3 LICENSING AND REGISTRATION 452
• 6.54 ISRAEL 452
  • 6.54.1 REGULATORY APPROVAL PROCESS 452
  • 6.54.2 TIMELINE 452
  • 6.54.3 REGULATORY APPROVAL AGENCIES 452
  • 6.54.4 LICENSING AND REGISTRATION 452
  • 6.54.5 POST-MARKETING SURVEILLANCE 453
• 6.55 ALGERIA 454
  • 6.55.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 454
  • 6.55.2 REGULATORY APPROVAL AGENCIES 454
  • 6.55.3 LICENSING AND REGISTRATION 454
• 6.56 JORDAN 454
  • 6.56.1 REGULATORY APPROVAL AGENCIES, PROCESS, PATHWAYS, AND TIMELINE 454
  • 6.56.2 LICENSING AND REGISTRATION 454
  • 6.56.3 POST-MARKETING SURVEILLANCE 454
• 6.57 BAHRAIN 455
  • 6.57.1 LICENSING AND REGISTRATION 455
  • 6.57.2 FUNDAMENTAL GUIDELINES FOR TRACEABILITY IN BAHRAIN 456
• 6.58 IRAQ 456
  • 6.58.1 REGULATORY APPROVAL PROCESS, AGENCIES, FUNCTION 456
• 6.59 IRAN 457
  • 6.59.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 457
  • 6.59.2 REGULATORY APPROVAL AGENCIES 457
  • 6.59.3 LICENSING AND REGISTRATION 458
• 6.60 LEBANON 458
  • 6.60.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 458
  • 6.60.2 REGULATORY APPROVAL AGENCIES 458
  • 6.60.3 LICENSING AND REGISTRATION 458
• 6.61 LIBYA 459
  • 6.61.1 REGULATORY APPROVAL AGENCIES AND FUNCTION 459
• 6.62 MOROCCO 459
  • 6.62.1 REGULATORY APPROVAL AGENCIES AND FUNCTION 459
• 6.63 OMAN 459
  • 6.63.1 REGULATORY APPROVAL AGENCIES AND REGISTRATION PROCESS 459
• 6.64 QATAR 460
  • 6.64.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 460
  • 6.64.2 REGULATORY APPROVAL AGENCIES 460
• 6.65 TUNISIA 460
  • 6.65.1 REGULATORY APPROVAL AGENCIES AND REGISTRATION PROCESS 460
  • 6.65.2 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES: 462

7 PIPELINE ANALYSIS OF THE GLOBAL FAT REDUCTION MARKET 464

8 MARKET ACCESS 471

• 8.1 MANUFACTURER AND STRATEGIC DEALS 471
• 8.2 CURRENT TREATMENT PRACTICES 471
• 8.3 IMPACT OF UPCOMING THERAPY 472

9 MARKET OVERVIEW 473

• 9.1 DRIVERS 475
  • 9.1.1 INCREASING DEMAND FOR MINIMALLY INVASIVE AND NON-INVASIVE PROCEDURES 475
  • 9.1.2 GROWING AESTHETIC CONSCIOUSNESS AND BEAUTY STANDARDS 476
  • 9.1.3 GROWING TECHNOLOGICAL ADVANCEMENTS 477
  • 9.1.4 DECREASED DISPARITY BETWEEN MEN AND WOMEN FOR AESTHETIC PROCEDURES 478
• 9.2 RESTRAINTS 479
  • 9.2.1 HIGH COST OF PROCEDURES 479
  • 9.2.2 INCREASED RISKS ASSOCIATED WITH THE PROCEDURES 480
  • 9.2.3 PRODUCT RECALL 480
• 9.3 OPPORTUNITIES 481
  • 9.3.1 CUSTOMIZED TREATMENT PLANS AND INTEGRATION WITH OTHER AESTHETIC PROCEDURES 481
  • 9.3.2 BELIEF AND TREND OF FAT REDUCTION IN YOUNG ADULTS 482
  • 9.3.3 FOCUS ON INCLUSIVITY AND DIVERSITY AND EXPANSION OF PRODUCT LINES 484
• 9.4 CHALLENGES 486
  • 9.4.1 LONG-TERM EFFICACY AND SUSTAINABILITY 486
  • 9.4.2 LONGER RECOVERY TIME OF THE PROCEDURE 486

10 GLOBAL FAT REDUCTION MARKET, BY TYPE 488

• 10.1 OVERVIEW 489
• 10.2 SURGICAL FAT REDUCTION 492
  • 10.2.1 LIPOSUCTION 493
    • 10.2.1.1 BY TYPE 494
      • 10.2.1.1.1 ULTRASOUND-ASSISTED LIPOSUCTION 494
      • 10.2.1.1.2 LASER-ASSISTED LIPOSUCTION 495
      • 10.2.1.1.3 TUMESCENT LIPOSUCTION 495
      • 10.2.1.1.4 SUPER-WET TECHNIQUE 495
    • 10.2.1.2 BY APPLICATION 495
      • 10.2.1.2.1 ABDOMINAL FAT 496
      • 10.2.1.2.2 THIGHS FAT 496
      • 10.2.1.2.3 BUTTOCK FAT 496
      • 10.2.1.2.4 UPPER-ARM FAT 496
      • 10.2.1.2.5 FACIAL FAT-DEPOSITS 496
      • 10.2.1.2.5.1 SUBMENTAL AREAS 497
      • 10.2.1.2.5.2 MALAR 497
      • 10.2.1.2.5.3 MANDIBULAR 497
      • 10.2.1.2.6 KNEE FAT 497
  • 10.2.2 SURGICAL REJUVENATION 497
    • 10.2.2.1 FACE LIFT 498
    • 10.2.2.2 NECK LIFT 498
  • 10.2.3 CHIN IMPLANT 498
    • 10.2.3.1 SILICONE CHIN IMPLANTS 499
    • 10.2.3.2 OTHERS 499
  • 10.2.4 PORUS IMPLANTS 499
    • 10.2.4.1 TEFLON 500
    • 10.2.4.2 GORE-TEX 500
    • 10.2.4.3 MEDPORE IMPLANTS 500
• 10.3 NON-INVASIVE FAT REDUCTION 500
  • 10.3.1 CRYOLIPOLYSIS 503
    • 10.3.1.1 COOL SCULPTING 503
    • 10.3.1.2 COOL SCULPTING ELITE 503
    • 10.3.1.3 COOL TONE 504
    • 10.3.1.4 OTHERS 504
      • 10.3.1.4.1 ABDOMINAL FAT 504
      • 10.3.1.4.2 THIGHS FAT 504
      • 10.3.1.4.3 BUTTOCK FAT 505
      • 10.3.1.4.4 UPPER-ARM FAT 505
      • 10.3.1.4.5 FACIAL FAT-DEPOSITS 505
      • 10.3.1.4.6 KNEE FAT 505
  • 10.3.2 ULTRASOUND 505
    • 10.3.2.1 INTERNAL ULTRASONIC LIPOSUCTION 506
    • 10.3.2.2 EXTERNAL ULTRASONIC LIPOSUCTION 506
      • 10.3.2.2.1 ABDOMINAL FAT 507
      • 10.3.2.2.2 THIGHS FAT 507
      • 10.3.2.2.3 BUTTOCK FAT 507
      • 10.3.2.2.4 UPPER-ARM FAT 507
      • 10.3.2.2.5 FACIAL FAT-DEPOSITS 507
      • 10.3.2.2.6 KNEE FAT 507
  • 10.3.3 RADIOFREQUENCY 508
    • 10.3.3.1 ABDOMINAL FAT 508
    • 10.3.3.2 THIGHS FAT 508
    • 10.3.3.3 BUTTOCK FAT 508
    • 10.3.3.4 UPPER-ARM FAT 508
    • 10.3.3.5 FACIAL FAT-DEPOSITS 509
    • 10.3.3.6 KNEE FAT 509
  • 10.3.4 LOW LEVEL LASER THERAPY 509
    • 10.3.4.1 ABDOMINAL FAT 509
    • 10.3.4.2 THIGHS FAT 509
    • 10.3.4.3 BUTTOCK FAT 510
    • 10.3.4.4 UPPER-ARM FAT 510
    • 10.3.4.5 FACIAL FAT-DEPOSITS 510
    • 10.3.4.6 KNEE FAT 510
  • 10.3.5 OTHERS 510
• 10.4 MINIMALLY INVASIVE 510
  • 10.4.1 INJECTION LIPOLYSIS 512
    • 10.4.1.1 DEOXYCHOLIC ACID INJECTIONS 512
      • 10.4.1.1.1 KYBELLA/BELKYRA 513
      • 10.4.1.1.1.1 FACIAL FAT-DEPOSITS 514
      • 10.4.1.1.1.2 UPPER-ARM FAT 514
      • 10.4.1.1.1.3 ABDOMINAL FAT 514
      • 10.4.1.1.1.4 THIGHS FAT 514
      • 10.4.1.1.1.5 KNEE FAT 514
      • 10.4.1.1.1.6 BUTTOCK FAT 514
      • 10.4.1.1.2 AQUALYX 515
      • 10.4.1.1.2.1 FACIAL FAT-DEPOSITS 515
      • 10.4.1.1.2.2 UPPER-ARM FAT 515
      • 10.4.1.1.2.3 ABDOMINAL FAT 515
      • 10.4.1.1.2.4 THIGHS FAT 516
      • 10.4.1.1.2.5 KNEE FAT 516
      • 10.4.1.1.2.6 BUTTOCK FAT 516
    • 10.4.1.2 PHOSPHATIDYLCHOLINE 516
      • 10.4.1.2.1 FACIAL FAT-DEPOSITS 517
      • 10.4.1.2.2 UPPER-ARM FAT 517
      • 10.4.1.2.3 ABDOMINAL FAT 517
      • 10.4.1.2.4 THIGHS FAT 517
      • 10.4.1.2.5 KNEE FAT 517
      • 10.4.1.2.6 BUTTOCK FAT 517
    • 10.4.1.3 OTHERS 517
  • 10.4.2 OTHERS 517

11 GLOBAL FAT REDUCTION MARKET, BY APPLICATION 518

• 11.1 OVERVIEW 519
• 11.2 ABDOMINAL FAT 522
• 11.3 THIGHS FAT 523
• 11.4 BUTTOCK FAT 524
• 11.5 UPPER-ARM FAT 525
• 11.6 FACIAL FAT-DEPOSITS 526
  • 11.6.1 SUBMENTAL AREAS 527
  • 11.6.2 MANDIBULAR 527
  • 11.6.3 MALAR 527
• 11.7 KNEE FAT 527

12 GLOBAL FAT REDUCTION MARKET, BY GENDER 529

• 12.1 OVERVIEW 530
• 12.2 FEMALE 533
• 12.3 MALE 534

13 GLOBAL FAT REDUCTION MARKET, BY AGE GROUP 535

• 13.1 OVERVIEW 536
• 13.2 ADULT 539
• 13.3 GERIATRIC 540
• 13.4 CHILD 541

14 GLOBAL FAT REDUCTION MARKET, BY END USER 543

• 14.1 OVERVIEW 544
• 14.2 HOSPITALS 547
  • 14.2.1 BY TYPE 548
    • 14.2.1.1 PRIVATE 548
    • 14.2.1.2 PUBLIC 548
  • 14.2.2 BY CATEGORY 548
    • 14.2.2.1 TIER 1 549
    • 14.2.2.2 TIER 2 549
    • 14.2.2.3 TIER 3 549
• 14.3 MULTISPECIALTY CLINICS 549
• 14.4 DERMATOLOGY CENTERS 550
• 14.5 MEDICAL SPAS AND BEAUTY CENTERS 551
• 14.6 OTHERS 552

15 GLOBAL FAT REDUCTION MARKET, BY DISTRIBUTION CHANNEL 554

• 15.1 OVERVIEW 555
• 15.2 DIRECT TENDERS 558
• 15.3 RETAIL SALES 559
• 15.4 THIRD PARTY DISTRIBUTORS 560
• 15.5 OTHERS 561

16 GLOBAL FAT REDUCTION MARKET, BY REGION 562

• 16.1 OVERVIEW 563
• 16.2 NORTH AMERICA 568
  • 16.2.1 U.S. 588
  • 16.2.2 CANADA 606
  • 16.2.3 MEXICO 623
  • 16.2.4 COSTA RICA 641
  • 16.2.5 DOMINICAN REPUBLIC 659
  • 16.2.6 PANAMA 677
  • 16.2.7 EL SALVADOR 695
  • 16.2.8 GUATEMALA 712
  • 16.2.9 HONDURAS 730
  • 16.2.10 NICARAGUA 747
• 16.3 EUROPE 764
  • 16.3.1 GERMANY 785
  • 16.3.2 TURKEY 804
  • 16.3.3 ITALY 823
  • 16.3.4 POLAND 842
  • 16.3.5 SPAIN 861
  • 16.3.6 RUSSIA 879
  • 16.3.7 FRANCE 896
  • 16.3.8 NETHERLANDS 914
  • 16.3.9 SWITZERLAND 933
  • 16.3.10 BELGIUM 952
  • 16.3.11 AUSTRIA 970
  • 16.3.12 NORWAY 989
  • 16.3.13 IRELAND 1007
  • 16.3.14 HUNGARY 1025
  • 16.3.15 LITHUANIA 1042
  • 16.3.16 AZERBAIJAN 1060
  • 16.3.17 U.K. 1077
  • 16.3.18 GEORGIA 1093
  • 16.3.19 UKRAINE 1110
  • 16.3.20 REST OF EUROPE 1128
• 16.4 ASIA PACIFIC 1129
  • 16.4.1 JAPAN 1149
  • 16.4.2 INDIA 1167
  • 16.4.3 CHINA 1184
  • 16.4.4 SOUTH KOREA 1202
  • 16.4.5 THAILAND 1220
  • 16.4.6 MALAYSIA 1237
  • 16.4.7 SINGAPORE 1255
  • 16.4.8 AUSTRALIA 1273
  • 16.4.9 PHILIPPINES 1290
  • 16.4.10 TAIWAN 1308
  • 16.4.11 INDONESIA 1325
  • 16.4.12 NEW ZEALAND 1342
  • 16.4.13 VIETNAM 1359
  • 16.4.14 PAKISTAN 1373
  • 16.4.15 UZBEKISTAN 1390
  • 16.4.16 MYANMAR 1407
  • 16.4.17 NEPAL 1423
  • 16.4.18 CAMBODIA 1439
  • 16.4.19 REST OF ASIA-PACIFIC 1456
• 16.5 MIDDLE EAST AND AFRICA 1457
  • 16.5.1 SAUDI ARABIA 1476
  • 16.5.2 EGYPT 1492
  • 16.5.3 U.A.E. 1508
  • 16.5.4 SOUTH AFRICA 1525
  • 16.5.5 ISRAEL 1541
  • 16.5.6 KUWAIT 1556
  • 16.5.7 QATAR 1573
  • 16.5.8 OMAN 1589
  • 16.5.9 BAHRAIN 1605
  • 16.5.10 LEBANON 1621
  • 16.5.11 ALGERIA 1638
  • 16.5.12 JORDAN 1655
  • 16.5.13 MOROCCO 1672
  • 16.5.14 IRAN 1689
  • 16.5.15 LIBIYA 1705
  • 16.5.16 IRAQ 1721
  • 16.5.17 TUNISIA 1738
  • 16.5.18 REST OF MIDDLE EAST AND AFRICA 1754
• 16.6 SOUTH AMERICA 1756
  • 16.6.1 BRAZIL 1774
  • 16.6.2 ARGENTINA 1788
  • 16.6.3 COLOMBIA 1802
  • 16.6.4 CHILE 1816
  • 16.6.5 PERU 1830
  • 16.6.6 EQUADOR 1843
  • 16.6.7 BOLIVIA 1856
  • 16.6.8 PARAGUAY 1869
  • 16.6.9 REST OF SOUTH AMERICA 1882

17 GLOBAL FAT REDUCTION MARKET, COMPANY LANDSCAPE 1883

• 17.1 COMPANY SHARE ANALYSIS: GLOBAL 1883
• 17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 1884
• 17.3 COMPANY SHARE ANALYSIS: EUROPE 1885
• 17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 1886

18 GLOBAL FAT REDUCTION MARKET, COMPANY LANDSCAPE COUNTRY WISE 1887

• 18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 1887
  • 18.1.1 COMPANY SHARE ANALYSIS: U.S. 1887
    • 18.1.1.1 ABBVIE INC. 1888
    • 18.1.1.2 CYNOSURE 1889
    • 18.1.1.3 ALMA LASERS 1890
    • 18.1.1.4 CANDELA CORPORATION 1891
    • 18.1.1.5 MERZ PHARMA 1892
  • 18.1.2 COMPANY SHARE ANALYSIS: CANADA 1893
    • 18.1.2.1 COMPANY SHARE ANALYSIS: CANADA 1893
    • 18.1.2.2 ABBVIE INC. 1894
    • 18.1.2.3 CYNOSURE 1895
    • 18.1.2.4 CANDELA CORPORATION 1896
    • 18.1.2.5 ALMA LASERS 1897

LIST OF FIGURES

• FIGURE 1 GLOBAL FAT REDUCTION MARKET: SEGMENTATION 235
• FIGURE 2 GLOBAL FAT REDUCTION MARKET: DATA TRIANGULATION 238
• FIGURE 3 GLOBAL FAT REDUCTION MARKET: DROC ANALYSIS 239
• FIGURE 4 GLOBAL FAT REDUCTION MARKET: GLOBAL VS. REGIONAL MARKET ANALYSIS 240
• FIGURE 5 GLOBAL FAT REDUCTION MARKET: COMPANY RESEARCH ANALYSIS 240
• FIGURE 6 GLOBAL FAT REDUCTION MARKET: INTERVIEW DEMOGRAPHICS 241
• FIGURE 7 GLOBAL FAT REDUCTION MARKET: MULTIVARIATE MODELLING 242
• FIGURE 8 GLOBAL FAT REDUCTION MARKET: DBMR MARKET POSITION GRID 243
• FIGURE 9 GLOBAL FAT REDUCTION MARKET: VENDOR SHARE ANALYSIS 244
• FIGURE 10 GLOBAL FAT REDUCTION MARKET: MARKET APPLICATION COVERAGE GRID 245
• FIGURE 11 GLOBAL FAT REDUCTION MARKET: SEGMENTATION 249
• FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL FAT REDUCTION MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD FROM 2023 TO 2033 250
• FIGURE 13 INCREASING DEMAND FOR NON-INVASIVE AND MINIMALLY INVASIVE AESTHETIC PROCEDURES IS EXPECTED TO DRIVE THE GLOBAL FAT REDUCTION MARKET GROWTH IN THE FORECAST PERIOD FROM 2023 TO 2033 251
• FIGURE 14 THE SURGICAL FAT REDUCTION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL FAT REDUCTION MARKET IN 2023 & 2033 251
• FIGURE 15 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR THE FAT REDUCTION MANUFACTURERS IN THE FORECAST PERIOD FROM 2023 TO 2033 252
• FIGURE 16 GMP COMPLIANCE FLOW CHART OF DRUG REVIEW PROCESS FOR CAMBODIA 431
• FIGURE 17 INSTITUTIONS INVOLVED IN THE APPROVAL PROCESS: 435
• FIGURE 18 LICENSING AND REGISTRATION: 436
• FIGURE 19 REGISTRATION PROCESS (STEPS OF REGISTRATION) 436
• FIGURE 20 PROCEDURE FOR THE REGISTRATION OF PHARMACEUTICAL PRODUCTS (GENERICS) 440
• FIGURE 21 REGISTRATION PROCESS OF THE MEDICINAL PRODUCTS INTENDED FOR HUMAN USE 461
• FIGURE 22 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL FAT REDUCTION MARKET 474
• FIGURE 23 GLOBAL FAT REDUCTION MARKET: BY TYPE, 2022 489
• FIGURE 24 GLOBAL FAT REDUCTION MARKET: BY TYPE, 2023-2033 (USD MILLION) 490
• FIGURE 25 GLOBAL FAT REDUCTION MARKET: BY TYPE, CAGR (2023-2033) 490
• FIGURE 26 GLOBAL FAT REDUCTION MARKET: BY TYPE, LIFELINE CURVE 491
• FIGURE 27 GLOBAL FAT REDUCTION MARKET: BY APPLICATION, 2022 519
• FIGURE 28 GLOBAL FAT REDUCTION MARKET: BY APPLICATION, 2023-2033 (USD MILLION) 520
• FIGURE 29 GLOBAL FAT REDUCTION MARKET: BY APPLICATION, CAGR (2023-2033) 520
• FIGURE 30 GLOBAL FAT REDUCTION MARKET: BY APPLICATION, LIFELINE CURVE 521
• FIGURE 31 GLOBAL FAT REDUCTION MARKET: BY GENDER, 2022 530
• FIGURE 32 GLOBAL FAT REDUCTION MARKET: BY GENDER, 2023-2033 (USD MILLION) 531
• FIGURE 33 GLOBAL FAT REDUCTION MARKET: BY GENDER, CAGR (2023-2033) 531
• FIGURE 34 GLOBAL FAT REDUCTION MARKET: BY GENDER, LIFELINE CURVE 532
• FIGURE 35 GLOBAL FAT REDUCTION MARKET: BY AGE GROUP, 2022 536
• FIGURE 36 GLOBAL FAT REDUCTION MARKET: BY AGE GROUP, 2023-2033 (USD MILLION) 537
• FIGURE 37 GLOBAL FAT REDUCTION MARKET: BY AGE GROUP, CAGR (2023-2033) 537
• FIGURE 38 GLOBAL FAT REDUCTION MARKET: BY AGE GROUP, LIFELINE CURVE 538
• FIGURE 39 GLOBAL FAT REDUCTION MARKET: BY END USER, 2022 544
• FIGURE 40 GLOBAL FAT REDUCTION MARKET: BY END USER, 2023-2033 (USD MILLION) 545
• FIGURE 41 GLOBAL FAT REDUCTION MARKET: BY END USER, CAGR (2023-2033) 545
• FIGURE 42 GLOBAL FAT REDUCTION MARKET: BY END USER, LIFELINE CURVE 546
• FIGURE 43 GLOBAL FAT REDUCTION MARKET: BY DISTRIBUTION CHANNEL, 2022 555
• FIGURE 44 GLOBAL FAT REDUCTION MARKET: BY DISTRIBUTION CHANNEL, 2023-2033 (USD MILLION) 556
• FIGURE 45 GLOBAL FAT REDUCTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2033) 556
• FIGURE 46 GLOBAL FAT REDUCTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 557
• FIGURE 47 GLOBAL FAT REDUCTION MARKET: SNAPSHOT (2022) 564
• FIGURE 48 GLOBAL FAT REDUCTION MARKET: BY REGION (2022) 565
• FIGURE 49 GLOBAL FAT REDUCTION MARKET: BY REGION (2023 & 2033) 565
• FIGURE 50 GLOBAL FAT REDUCTION MARKET: BY REGION (2022 & 2033) 566
• FIGURE 51 GLOBAL FAT REDUCTION MARKET: BY TYPE (2023-2033) 566
• FIGURE 52 NORTH AMERICA FAT REDUCTION MARKET: SNAPSHOT (2022) 569
• FIGURE 53 NORTH AMERICA FAT REDUCTION MARKET: BY COUNTRY (2022) 570
• FIGURE 54 NORTH AMERICA FAT REDUCTION MARKET: BY COUNTRY (2023 & 2033) 570
• FIGURE 55 NORTH AMERICA FAT REDUCTION MARKET: BY COUNTRY (2022 & 2033) 571
• FIGURE 56 NORTH AMERICA FAT REDUCTION MARKET: BY TYPE (2023-2033) 571
• FIGURE 57 EUROPE FAT REDUCTION MARKET: SNAPSHOT (2022) 765
• FIGURE 58 EUROPE FAT REDUCTION MARKET: BY COUNTRY (2022) 766
• FIGURE 59 EUROPE FAT REDUCTION MARKET: BY COUNTRY (2023 & 2033) 766
• FIGURE 60 EUROPE FAT REDUCTION MARKET: BY COUNTRY (2022 & 2033) 767
• FIGURE 61 EUROPE FAT REDUCTION MARKET: BY TYPE (2023-2033) 767
• FIGURE 62 ASIA-PACIFIC FAT REDUCTION MARKET: SNAPSHOT (2022) 1130
• FIGURE 63 ASIA-PACIFIC FAT REDUCTION MARKET: BY COUNTRY (2022) 1131
• FIGURE 64 ASIA-PACIFIC FAT REDUCTION MARKET: BY COUNTRY (2023 & 2033) 1131
• FIGURE 65 ASIA-PACIFIC FAT REDUCTION MARKET: BY COUNTRY (2022 & 2033) 1132
• FIGURE 66 ASIA-PACIFIC FAT REDUCTION MARKET: BY TYPE (2023-2033) 1132
• FIGURE 67 MIDDLE EAST AND AFRICA FAT REDUCTION MARKET: SNAPSHOT (2022) 1458
• FIGURE 68 MIDDLE EAST AND AFRICA FAT REDUCTION MARKET: BY COUNTRY (2022) 1459
• FIGURE 69 MIDDLE EAST AND AFRICA FAT REDUCTION MARKET: BY COUNTRY (2023 & 2033) 1459
• FIGURE 70 MIDDLE EAST AND AFRICA FAT REDUCTION MARKET: BY COUNTRY (2022 & 2033) 1460
• FIGURE 71 MIDDLE EAST AND AFRICA FAT REDUCTION MARKET: BY TYPE (2023-2033) 1460
• FIGURE 72 SOUTH AMERICA FAT REDUCTION MARKET: SNAPSHOT (2022) 1757
• FIGURE 73 SOUTH AMERICA FAT REDUCTION MARKET: BY COUNTRY (2022) 1758
• FIGURE 74 SOUTH AMERICA FAT REDUCTION MARKET: BY COUNTRY (2023 & 2033) 1758
• FIGURE 75 SOUTH AMERICA FAT REDUCTION MARKET: BY COUNTRY (2022 & 2033) 1759
• FIGURE 76 SOUTH AMERICA FAT REDUCTION MARKET: BY TYPE (2023-2033) 1759
• FIGURE 77 GLOBAL FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1883
• FIGURE 78 NORTH AMERICA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1884
• FIGURE 79 EUROPE FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1885
• FIGURE 80 ASIA-PACIFIC FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1886
• FIGURE 81 THE U.S. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1887
• FIGURE 82 ABBVIE INC.IN U.S. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1888
• FIGURE 83 CYNOSURE IN U.S. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1889
• FIGURE 84 ALMA LASERS IN U.S. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1890
• FIGURE 85 CANDELA CORPORATION IN U.S. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1891
• FIGURE 86 MERZ PHARMA IN U.S. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1892
• FIGURE 87 THE CANADA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1893
• FIGURE 88 ABBVIE INC.IN CANADA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1894
• FIGURE 89 CYNOSURE IN CANADA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1895
• FIGURE 90 CANDELA CORPORATION IN CANADA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1896
• FIGURE 91 ALMA LASERS IN CANADA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1897
• FIGURE 92 MERZ PHARMA IN CANADA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1898
• FIGURE 93 THE MEXICO FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1899
• FIGURE 94 ABBVIE INC.IN MEXICO FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1900
• FIGURE 95 ALMA LASERS IN MEXICO FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1901
• FIGURE 96 CANDELA CORPORATION IN MEXICO FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1902
• FIGURE 97 MERZ PHARMA IN CANADA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1903
• FIGURE 98 THE COSTA RICA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1904
• FIGURE 99 ALMA LASERS IN DOMINICAN REPUBLIC FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1905
• FIGURE 100 CANDELA CORPORATION IN COSTA RICA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1906
• FIGURE 101 DEXLEVO AESTHETICS IN GUATEMALA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1907
• FIGURE 102 THE DOMINICAN REPUBLIC FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1908
• FIGURE 103 ABBVIE INC IN DOMINICAN REPUBLIC FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1909
• FIGURE 104 ALMA LASERS IN DOMINICAN REPUBLIC FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1910
• FIGURE 105 THE GUATEMALA S FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1911
• FIGURE 106 ALMA LASERS IN GUATEMALA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1912
• FIGURE 107 CANDELA CORPORATION IN GUATEMALA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1913
• FIGURE 108 THE HONDURUS FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1914
• FIGURE 109 ALMA LASERS IN HONDURUS FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1915
• FIGURE 110 CANDELA CORPORATION IN HONDURUS FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1916
• FIGURE 111 THE PANAMA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1917
• FIGURE 112 ALMA LASERS IN PANAMA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1918
• FIGURE 113 CANDELA CORPORATION IN PANAMA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1919
• FIGURE 114 THE EL SALVADOR FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1920
• FIGURE 115 ALMA LASERS IN EL SALVADOR FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1921
• FIGURE 116 THE NICARAGUA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1922
• FIGURE 117 ALMA LASERS IN NICARAGUA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1923
• FIGURE 118 THE GERMANY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1924
• FIGURE 119 ABBVIE INC.IN GERMANY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1925
• FIGURE 120 CYNOSURE IN GERMANY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1926
• FIGURE 121 ALMA LASERS IN GERMANY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1927
• FIGURE 122 CANDELA CORPORATION IN GERMANY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1928
• FIGURE 123 MERZ PHARMA IN U.S. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1929
• FIGURE 124 THE FRANCE FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1930
• FIGURE 125 ABBVIE INC.IN FRANCE FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1931
• FIGURE 126 CYNOSURE IN FRANCE FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1932
• FIGURE 127 CANDELA CORPORATION IN FRANCE FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1933
• FIGURE 128 VENOUS CONCEPT IN FRANCE FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1934
• FIGURE 129 THE U.K. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1935
• FIGURE 130 ABBVIE INC.IN U.K. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1936
• FIGURE 131 CYNOSURE IN U.K. IN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1937
• FIGURE 132 ALMA LASERS IN U.K FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1938
• FIGURE 133 CANDELA CORPORATION IN U.K. IN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1939
• FIGURE 134 MERZ PHARMA IN U.S. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1940
• FIGURE 135 THE ITALY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1941
• FIGURE 136 ABBVIE INC.IN ITALY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1942
• FIGURE 137 CANDELA CORPORATION IN ITALY IN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1943
• FIGURE 138 MERZ PHARMA IN ITALY IN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1944
• FIGURE 139 MENTOR WORLDWIDE LLC IN BRAZIL FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1945
• FIGURE 140 THE SPAIN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1946
• FIGURE 141 ABBVIE INC.IN SPAIN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1947
• FIGURE 142 CYNOSURE IN SPAIN IN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1948
• FIGURE 143 CANDELA CORPORATION IN SPAIN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1949
• FIGURE 144 THE RUSSIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1950
• FIGURE 145 ABBVIE INC.IN RUSSIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1951
• FIGURE 146 CANDELA CORPORATION IN RUSSIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1952
• FIGURE 147 MERZ PHARMA IN RUSSIA IN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1953